Structural Description: Cagrilintide is a synthetic, long-acting acylated analog of human amylin (a 37-amino acid peptide). It is modified with a $C_{20}$ fatty diacid (eicosanedioic acid) conjugated via a hydrophilic glutamic acid linker at the Lysine residue of position 1 to enable robust albumin binding and prolong its research half-life.
Researchers are actively investigating Cagrilintide across several key metabolic and physiological domains, including:
Dual Amylin & Calcitonin Receptor Agonism: Evaluating its nonselective activation of both amylin receptors (AMYR) and calcitonin receptors (CTR) to study downstream neuroendocrine satiety pathways.
Synergistic Co-Administration with GLP-1 Agonists: Investigating its additive physiological effects on appetite regulation, caloric intake reduction, and body composition when studied alongside GLP-1 receptor agonists (such as semaglutide).
Gastric Emptying and GI Transit Dynamics: Studying its pharmacodynamics concerning delayed gastric transit, postprandial glucose excursions, and gastrointestinal hormone release patterns.
Energy Expenditure and Lipid Metabolism: Assessing its contribution to resting metabolic rate, fat oxidation, and adipose tissue signaling cascades in animal models of metabolic syndrome.
Homeostatic & Hedonic Satiety Signaling: Exploring how the peptide modulates neuronal activation in both the hindbrain (homeostatic control) and reward-related pathways (hedonic control) to decrease food motivation.
Reviews
There are no reviews yet.